Mon panier

Cynomolgus / Rhesus macaque OX40 Ligand / TNFSF4 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
OXL-R5259-100ug
$360.00
OXL-R5259-1mg (500ug X 2)
$2380.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    OX40L, TNFSF4, CD252, Glycoprotein Gp34, TXGP1, CD134 ligand, CD134L

  • Source

    Cynomolgus / Rhesus macaque OX40 Ligand, Mouse IgG2a Fc Tag (OXL-R5259) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # F7FL80-1). In the region Gln 51 - Leu 183, the amino acid sequences of Cynomolgus and Rhesus macaque OX40 Ligand are identical.

    Predicted N-terminus: Glu

    Request for sequence
  • Molecular Characterization

    OX40 Ligand Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a mouse IgG2a Fc tag at the N-terminus.

    The protein has a calculated MW of 42.5 kDa. The protein migrates as 47-58 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    The protein is designed as a trimer.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    OX40 Ligand SDS-PAGE

    Cynomolgus / Rhesus macaque OX40 Ligand, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    OX40 Ligand SEC-MALS

    The purity of Cynomolgus / Rhesus macaque OX40 Ligand, Mouse IgG2a Fc Tag (Cat. No. OXL-R5259) is more than 85% and the molecular weight of this protein is around 270-300 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     OX40 Ligand ELISA

    Immobilized Cynomolgus / Rhesus macaque OX40, His Tag (Cat. No. OX0-C5220) at 2 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque OX40 Ligand, Mouse IgG2a Fc Tag (Cat. No. OXL-R5259) with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Tumor necrosis factor ligand superfamily member 4

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    13 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte